Inactive Instrument

Analyst Reco. Xeris Biopharma Holdings, Inc. Nasdaq

Equities

Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target	Mar. 28	MT
Craig-Hallum Initiates Xeris Biopharma Holdings at Buy Rating With $4.50 Price Target	23-08-28	MT
SVB Securities Trims Xeris Biopharma Price Target to $5 From $6, Maintains Outperform Rating	23-01-27	MT
Jefferies Starts Xeris Biopharma Holdings at Buy With $4 Price Target	22-10-21	MT
Craig-Hallum Starts Xeris Biopharma Holdings at Buy With $6.50 Price Target	22-04-28	MT
Mizuho Securities Adjusts Xeris Biopharma Holdings' Price Target to $6 From $8, Keeps Buy Rating	22-03-16	MT
SVB Leerink Adjusts Xeris Biopharma Holdings Price Target to $6 From $8, Maintains Outperform Rating	22-02-16	MT
SVB Leerink Raises Price Target on Xeris Biopharma Holdings to $8 From $6, Maintains Outperform Rating	21-12-31	MT
HC Wainwright Raises Price Target on Xeris Biopharma Holdings to $5.40 From $4.25, Maintains Buy Rating	21-12-31	MT
SVB Leerink Starts Xeris Pharmaceuticals at Outperform With $6 Price Target	21-11-17	MT
HC Wainwright Starts Xeris Pharmaceuticals at Buy With $4 Price Target	21-10-29	MT

No results for this search